Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Details
News Market Reaction – ONCY
The recorded move for ONCY in the trading session of this news was -1.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Date: Friday, March 1, 2024
Time: 11:30 a.m. ET
Location: Ritz Carlton Hotel New Orleans, Acadia Room 2nd Floor
Webcast Link: Available by clicking here
Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please submit a request to the conference organizers or email jpatton@oncolytics.ca
A live webcast of the Company's presentation will also be available on the Investor Relations page of Oncolytics' website (LINK).
Additional information about the event can be found on the official website by clicking here.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in phase 2 studies in breast and pancreatic cancers. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Logo - https://mma.prnewswire.com/media/1762876/4566032/Oncolytics_Biotech_New_Logo.jpg
Company Contact Jon Patton Director of IR & Communication +1-858-886-7813 | Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-917-679-9282 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-presentation-at-the-cancer-advocacy-group-of-louisianas-3rd-annual-neauxcancer-conference-302074097.html
SOURCE Oncolytics Biotech® Inc.